AOD-9604 in Guadalupe Enríquez — Fat Loss Peptide Research Guide
AOD-9604 research guide for Guadalupe Enríquez. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.
For anyone in Guadalupe Enríquez looking to source AOD-9604, the key fact to understand is that this compound is distributed via specialist online vendors. What this means for Guadalupe Enríquez researchers is that physical proximity is irrelevant compared to your ability to evaluate vendor quality — and those evaluation tools are accessible to anyone. The key verification criteria for AOD-9604 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-matched Certificate of Analysis. The sections below cover what Guadalupe Enríquez researchers need to know about purchasing, testing, and working with AOD-9604 for legitimate research applications.
The Science Behind AOD-9604
AOD-9604 belongs to the growth hormone secretagogue (GHS) class, compounds that stimulate pulsatile growth hormone release by acting on the ghrelin receptor (GHSR-1a) or growth hormone releasing hormone (GHRH) receptor. Ipamorelin, GHRP-2, GHRP-6, and Hexarelin all work primarily through GHSR-1a agonism, producing GH pulses with varying specificity profiles. CJC-1295 and Sermorelin work through the GHRH receptor, mimicking the natural hypothalamic signal for GH release. The downstream effect in both cases is increased pulsatile GH secretion and subsequent IGF-1 production in the liver. For researchers in Guadalupe Enríquez studying the GH-IGF-1 axis, this mechanistic clarity makes the GHS class a productive experimental tool.
Where to Buy AOD-9604 — A Researcher's Guide
Vetting AOD-9604 vendors requires starting from the COA: access the batch-specific certificate before purchasing, not after. A COA for AOD-9604 should include: HPLC purity percentage with the underlying chromatogram, mass spectrometry data establishing the correct molecular weight, endotoxin test results, and a residual solvent panel — all traceable to your batch. Signs of a credible vendor beyond COA quality: multi-year operating history, customer service that can discuss analytical methods, and cold chain packaging that protects product integrity. For Guadalupe Enríquez researchers making a first AOD-9604 purchase: apply these quality criteria before ordering, order conservatively at first, and check that batch numbers on your vial match the COA before use.
Order AOD-9604 — ships to Guadalupe Enríquez
COA-verified · International tracking · Research grade
As a research compound, AOD-9604 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is defined by animal study data and limited human studies. Storage requirements for AOD-9604: lyophilised powder at minus 20°C, reconstituted solution stored refrigerated at 2-8°C and used within 30 days; reconstitute only with bac water. Quality AOD-9604 sourcing is inseparable from safety — bacterial endotoxin contamination, incorrect identity, and breakdown products are all safety issues that proper COA verification addresses. Researchers combining AOD-9604 with other compounds should examine published studies for potential interaction data before running stacked compound experiments.
Frequently Asked Questions
What is the clinical trial history of AOD-9604?
AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.
What is AOD-9604?
AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.
How does AOD-9604 differ from growth hormone?
AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.
